LaManna, updates devilray Ph.D.,chairman of tampa bay rays retells the Anatomy Department and Professor in the Neurology,Physiology/Biophysics and Neuroscience departments at the Case Western ReserveUniversity School of Medicine (Cleveland, Ohio). Twenty-four rats were randomlyassigned to four drug- and vehicle-treated groups (six rats per group) andexposed to either normal atmospheric oxygen or hypobaric hypoxia for 10 days.Drug-treated rats were administered intraperitoneal (abdominal) injections ofarimoclomol daily, while control rats were given only the solution in whicharimoclomol was dissolved. Hypoxic rats were kept in hypobaric chambers at aconstant pressure equivalent to one-half of sea level (0.5 atmospheres), withthe exception of approximately three hours daily in which they were returned tonormal atmospheric pressure for behavioral tests. Normoxic rats were housed inthe same room to ensure identical ambient conditions. Tissues from all trialrats were valuated for markers of hypoxic damage. Trial data indicated that arimoclomol improved both cognitive and motorperformance during the adaptation to simulated high-altitude exposure. Theseresults included improved ability to explore a maze, and ability to recognizeand explore a novel object, which was evaluated through memory tests.
Inaddition, signs of programmed cell death, or apoptosis, in the brain duringhypoxic exposure were diminished and hypoxia-induced inflammatory responses werealso suppressed by arimoclomol devilrays . About ArimoclomolArimoclomol, a molecular chaperone regulator drug candidate, is being consideredas a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease)and stroke recovery tropicana field concerts . Arimoclomol has been studied in seven Phase 1 and two Phase2 clinical trials without any significant adverse events tropicana field event . CytRx`s Phase 2bclinical trial with arimoclomol as a treatment for ALS was placed on clinicalhold by the FDA in January 2008, unrelated to any data generated by humanstudies, and CytRx expects to submit this quarter to the FDA data fromadditional preclinical toxicology studies to potentially resolve this issue tropicana field events . TheCompany anticipates a response from the FDA in the third quarter. In February2009, CytRx announced the commencement of a Phase 2/3 adaptive clinical trial tostudy arimoclomol in a subset of patients with the inherited or familial form ofALS or Lou Gehrig's disease. About Molecular Chaperone RegulationCytRx is a leader in molecular chaperone regulation technology.
The Companycurrently has two orally administered, clinical-stage drug candidates andrecently discovered a series of additional compounds that may provide a pipelinefor additional drug candidates devilrays baseball . The Company's drug candidates are believed tofunction by regulating a normal cellular protein repair pathway through theactivation or inhibition of "molecular chaperones." Because damaged proteins arethought to play a role in many diseases, activation of molecular chaperones thathelp to reduce the accumulation of misfolded proteins may have therapeuticefficacy in a broad range of disease states tampa bay rays . Similarly, CytRx believes that theinhibition of molecular chaperones that normally help protect cancer cells fromtoxic misfolded proteins may result in the selective destruction of cancercells tropicana field concerts . About CytRx CorporationCytRx Corporation is a biopharmaceutical research and development companyengaged in the development of high-value human therapeutics tropicana field event .
The CytRx drugdevelopment pipeline includes programs in clinical development for cancerindications, including tamibarotene in a registration study for the treatment ofacute promyelocytic leukemia (APL) devilrays tickets . CytRx is developing two drug candidatesbased on its industry-leading molecular chaperone technology, which aims torepair or degrade misfolded proteins associated with disease tropicana field events . CytRx alsomaintains a 45% equity interest in publicly traded RXi Pharmaceuticals, Inc.(NASDAQ: RXII) tampa bay rays . For more information on the Company, visit Forward-Looking StatementsThis press release contains forward-looking statements within the meaning ofSection 21E of the Securities Exchange Act of 1934, as amended . All forward-lookingstatements are based upon information available to CytRx on the date thestatements are first published. CytRx undertakes no obligation to publiclyupdate or revise any forward-looking statements, whether as a result of newinformation, future events or otherwise. Legend Securities, Inc.Thomas Wagner800-385-5790 x152718-233-2600 Copyright Business Wire 2009.
Comments are closed.